Therapeutics Pipeline

Discovery of Dual-domain Drugs

Human diseases are often mediated by more than one pathological factor or pathway. Safer and more effective therapies may entail the specific delivery of protein drugs to act on these factors, and may reduce side effects. We have genetically added a functional fusion partner such as IL-1 receptor antagonist to an existing protein drug for:

  • A two-domain protein drug goes to disease site together, thus having synergy.
  • A two-domain protein drug has longer biologic life.
  • A two-domain protein drug has improved efficacy.
  • A two-domain protein drug has different tissue distribution profile from that of individual drugs.
  • A two-domain protein drug targets disease site, thus having less side-effect.
  • A two-domain drug is a novel molecular entity.

AMPROTEIN DRUG PIPELINES AT NONCLINICAL STAGE

  1. AMP18BP1RA (IL-18bp-Fc-IL-1ra)
  2. AMPT1RA (TNFR1-Fc-IL-1ra)

    3. Clinical indications: Psoriasis, tumor metastasis, ischemic heart diseases.

  3. AMP4R1RA (IL-4R-Fc-IL-1ra)

    4. Clinical indication: Asthma.

  4. AMPE4L (Exendin4-Fc-Leptin)
  5. AMPPL (PYY-Fc-Leptin)
  6. AMPSL (Symlin-Fc-Leptin)

    7. Clinical indication: Diabetes complicated with obesity or obesity complicated with diabetes.

One advantage of dual-domain protein therapeutics is the ability to inhibit the action of two ligands that act on the same or independent pathways

Dual Domain Abs

Dual Domain Abs Data